Biogen (NASDAQ:BIIB) is preparing to release its quarterly earnings on Friday, 2026-02-06. Here's a brief overview of what investors should keep in mind before the announcement.

Analysts expect Biogen to report an earnings per share (EPS) of $1.62.

Anticipation surrounds Biogen's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.

New investors should understand that while earnings performance is important, market reactions are often driven by guidance.

Earnings History Snapshot

During the last quarter, the company reported an EPS beat by $0.92, leading to a 3.11% increase in the share price on the subsequent day.

Here's a look at Biogen's past performance and the resulting price change:

Tracking Biogen's Stock Performance

Shares of Biogen were trading at $185.45 as of February 04. Over the last 52-week period, shares are up 31.2%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.

Analysts' Perspectives on Biogen

For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Biogen.

Biogen has received a total of 9 ratings from analysts, with the consensus rating as Neutral. With an average one-year price target of $179.0, the consensus suggests a potential 1.27% upside.

Peer Ratings Comparison

The analysis below examines the analyst ratings and average 1-year price targets of and Biogen, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.

Insights: Peer Analysis

The peer analysis summary provides a snapshot of key metrics for and Biogen, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

Key Takeaway:

Biogen is positioned in the middle among its peers for consensus rating. It ranks in the middle for revenue growth. Biogen is in the middle for gross profit. It is in the middle for return on equity.

Unveiling the Story Behind Biogen

Biogen: A Financial Overview

Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.

Revenue Growth: Biogen displayed positive results in 3 months. As of 30 September, 2025, the company achieved a solid revenue growth rate of approximately 2.79%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Biogen's net margin excels beyond industry benchmarks, reaching 18.4%. This signifies efficient cost management and strong financial health.

Return on Equity (ROE): Biogen's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.6%, the company may face hurdles in achieving optimal financial performance.

Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.62%, the company showcases effective utilization of assets.

Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.36.

To track all earnings releases for Biogen visit their earnings calendar on our site.

This article was generated by Benzinga's automated content engine and reviewed by an editor.